KR102759231B1 - 키나제 억제제로서의 아미노피롤로트리아진 - Google Patents

키나제 억제제로서의 아미노피롤로트리아진 Download PDF

Info

Publication number
KR102759231B1
KR102759231B1 KR1020207024141A KR20207024141A KR102759231B1 KR 102759231 B1 KR102759231 B1 KR 102759231B1 KR 1020207024141 A KR1020207024141 A KR 1020207024141A KR 20207024141 A KR20207024141 A KR 20207024141A KR 102759231 B1 KR102759231 B1 KR 102759231B1
Authority
KR
South Korea
Prior art keywords
trifluoromethyl
amino
triazin
pyrrolo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207024141A
Other languages
English (en)
Korean (ko)
Other versions
KR20200115550A (ko
Inventor
스콧 헌터 워터슨
무루가이아 안다판 무루가이아 수바이아
캐롤린 다이앤 드지에르바
후아 공
제이슨 엠. 게르논
준칭 궈
에이미 씨. 하트
구앙린 뤄
존 이. 마코르
윌리엄 제이. 핏츠
지안리앙 시
브라이언 리 베나블레스
캐롤린 에이. 웨이겔트
용-진 우
지젠 바르바라 젱
싱-유엔 싯
지 첸
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20200115550A publication Critical patent/KR20200115550A/ko
Application granted granted Critical
Publication of KR102759231B1 publication Critical patent/KR102759231B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020207024141A 2018-01-26 2019-01-24 키나제 억제제로서의 아미노피롤로트리아진 Active KR102759231B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622415P 2018-01-26 2018-01-26
US62/622,415 2018-01-26
PCT/US2019/014918 WO2019147782A1 (en) 2018-01-26 2019-01-24 Aminopyrrolotriazines as kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20200115550A KR20200115550A (ko) 2020-10-07
KR102759231B1 true KR102759231B1 (ko) 2025-01-22

Family

ID=65363405

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024141A Active KR102759231B1 (ko) 2018-01-26 2019-01-24 키나제 억제제로서의 아미노피롤로트리아진

Country Status (16)

Country Link
US (1) US11618753B2 (cg-RX-API-DMAC7.html)
EP (1) EP3743430B1 (cg-RX-API-DMAC7.html)
JP (1) JP7307734B2 (cg-RX-API-DMAC7.html)
KR (1) KR102759231B1 (cg-RX-API-DMAC7.html)
CN (1) CN112262139B (cg-RX-API-DMAC7.html)
AR (1) AR114186A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019211382B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014516A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088548A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091777A1 (cg-RX-API-DMAC7.html)
ES (1) ES2959399T3 (cg-RX-API-DMAC7.html)
IL (1) IL276269A (cg-RX-API-DMAC7.html)
MX (1) MX2020007531A (cg-RX-API-DMAC7.html)
SG (1) SG11202007035YA (cg-RX-API-DMAC7.html)
TW (1) TW201940485A (cg-RX-API-DMAC7.html)
WO (1) WO2019147782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580220B1 (en) 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
DK3704118T3 (da) 2017-10-30 2022-03-14 Bristol Myers Squibb Co Aminoimidazopyrazin som kinasehæmmere
EP3849969B1 (en) 2018-09-13 2023-04-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
EP3849968B1 (en) 2018-09-13 2022-12-21 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
WO2021067654A1 (en) 2019-10-03 2021-04-08 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR20220139947A (ko) * 2020-02-07 2022-10-17 샌트랄 글래스 컴퍼니 리미티드 경화성 조성물, 경화물, 전자 디바이스, 표시 장치, 광학 부재, 중합체, 감광성 조성물, 패턴 및 화합물
WO2022007921A1 (zh) * 2020-07-10 2022-01-13 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
CN111925345B (zh) * 2020-08-21 2023-09-29 上海科利生物医药有限公司 一种手性2-氨甲基四氢呋喃的制备方法
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
CN116745361A (zh) * 2021-02-10 2023-09-12 中央硝子株式会社 树脂组合物、树脂膜、基材、聚合物以及聚合性单体
CN113563214B (zh) * 2021-07-06 2024-02-02 山东鲁泰控股集团有限公司石墨烯高分子复合材料研发中心 一种氨基乙酸的合成方法
CN113527220A (zh) * 2021-07-26 2021-10-22 京博农化科技有限公司 一种脱硫丙硫菌唑异构体的合成方法
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514882A (ja) 2005-11-02 2009-04-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
JP2009519222A (ja) 2005-11-17 2009-05-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 縮合2環系mTOR阻害剤
WO2011013729A1 (ja) 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Ttk阻害作用を有する縮合イミダゾール誘導体
JP2013523756A (ja) 2010-03-31 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
WO2016064958A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
WO2016064957A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007064931A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
IL266563B (en) 2009-10-06 2022-09-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
EP3580220B1 (en) 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
DK3704118T3 (da) 2017-10-30 2022-03-14 Bristol Myers Squibb Co Aminoimidazopyrazin som kinasehæmmere
EP3849968B1 (en) 2018-09-13 2022-12-21 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
EP3849969B1 (en) 2018-09-13 2023-04-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514882A (ja) 2005-11-02 2009-04-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
JP2009519222A (ja) 2005-11-17 2009-05-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 縮合2環系mTOR阻害剤
WO2011013729A1 (ja) 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Ttk阻害作用を有する縮合イミダゾール誘導体
JP2013523756A (ja) 2010-03-31 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
WO2016064958A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
WO2016064957A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors

Also Published As

Publication number Publication date
EA202091777A1 (ru) 2020-10-14
TW201940485A (zh) 2019-10-16
KR20200115550A (ko) 2020-10-07
CA3088548A1 (en) 2019-08-01
ES2959399T3 (es) 2024-02-26
IL276269A (en) 2020-09-30
MX2020007531A (es) 2020-09-09
JP7307734B2 (ja) 2023-07-12
BR112020014516A2 (pt) 2020-12-08
SG11202007035YA (en) 2020-08-28
EP3743430B1 (en) 2023-08-02
CN112262139B (zh) 2023-07-25
AU2019211382B2 (en) 2022-06-16
US20200347071A1 (en) 2020-11-05
EP3743430A1 (en) 2020-12-02
US11618753B2 (en) 2023-04-04
WO2019147782A1 (en) 2019-08-01
AR114186A1 (es) 2020-07-29
CN112262139A (zh) 2021-01-22
AU2019211382A1 (en) 2020-09-17
JP2021511363A (ja) 2021-05-06

Similar Documents

Publication Publication Date Title
KR102759231B1 (ko) 키나제 억제제로서의 아미노피롤로트리아진
US12157733B2 (en) Aminotriazolopyridines as kinase inhibitors
EP3704118B1 (en) Aminoimidazopyridazines as kinase inhibitors
CN104254533B (zh) 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
CN104169275B (zh) 用作激酶抑制剂的三唑取代的吡啶化合物
CN104159896B (zh) 用作激酶抑制剂的杂环取代的吡啶基化合物
KR102906523B1 (ko) 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
KR20210106441A (ko) 사이클릭 우레아
IL279482B1 (en) Thiophene derivatives for the treatment of disorders caused by ige
EA042342B1 (ru) Аминопирролотриазины в качестве ингибиторов киназы
WO2025170939A1 (en) Proteasome inhibitors for the treatment of malaria
EA042124B1 (ru) Аминоимидазопиридазины в качестве ингибиторов киназ

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200821

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220124

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240402

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241022

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250120

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250120

End annual number: 3

Start annual number: 1

PG1601 Publication of registration